Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
, 38 (32), 6065-6081

The MRVI1-AS1/ATF3 Signaling Loop Sensitizes Nasopharyngeal Cancer Cells to Paclitaxel by Regulating the Hippo-TAZ Pathway

Affiliations

The MRVI1-AS1/ATF3 Signaling Loop Sensitizes Nasopharyngeal Cancer Cells to Paclitaxel by Regulating the Hippo-TAZ Pathway

Yuxing Zhu et al. Oncogene.

Abstract

Long non-coding RNA (lncRNA) plays an important role in malignant tumor occurrence, development, and chemoresistance, but the mechanism of how they affect nasopharyngeal cancer (NPC) paclitaxel chemosensitivity is unclear. In this study, lncRNA array of CNE-1 and HNE-2 paclitaxel-resistant cells and their parental strains revealed that the paclitaxel-resistant strains had significantly lower MRVI1-AS1 (murine retrovirus integration site 1 homolog antisense RNA 1) expression than the parental strains, and that MRVI1-AS1 overexpression in vitro and in vivo increased paclitaxel chemosensitivity. Further, MRVI1-AS1 upregulated ATF3 (activating transcription factor 3) by simultaneously inhibiting miR-513a-5p (microRNA-513a-5p) and miR-27b-3p expression levels to increase NPC paclitaxel chemosensitivity. Chromatin immunoprecipitation and quantitative real-time PCR showed that ATF3 could feed-back MRVI1-AS1 regulation positively. Furthermore, MRVI1-AS1 and ATF3 could form a positive feedback loop, which promoted the expression of RASSF1 (Ras association domain family member 1), a Hippo-TAZ (tafazzin) signaling pathway regulatory factor, thereby inhibiting TAZ expression. The MTT (3-[4,5-dimethylthiazol-2-yl]-2,5 diphenyltetrazolium bromide) assay and flow cytometry showed that the decreased TAZ increased NPC cell paclitaxel chemosensitivity. Overall, the results indicate that the MRVI1-AS1/ATF3 signaling pathway can increase NPC paclitaxel chemosensitivity by modulating the Hippo-TAZ signaling pathway. Therefore, targeting the loop may be a new NPC treatment strategy.

Similar articles

See all similar articles

Cited by 1 article

References

    1. Proc Natl Acad Sci U S A. 2016 Nov 8;113(45):12739-12744 - PubMed

References

    1. Clin Cancer Res. 2017 Sep 15;23(18):5573-5584 - PubMed

References

    1. Nat Rev Genet. 2016 Jan;17(1):47-62 - PubMed

References

    1. Cell Death Dis. 2016 Nov 3;7(11):e2454 - PubMed

References

    1. Oncol Rep. 2016 Oct;36(4):1861-7 - PubMed

References

    1. Genome Biol. 2014 Jan 07;15(1):R6 - PubMed

References

    1. Carcinogenesis. 2018 Feb 9;39(2):98-108 - PubMed

References

    1. Nat Rev Drug Discov. 2017 Mar;16(3):167-179 - PubMed

References

    1. Theranostics. 2017 Oct 17;7(19):4825-4835 - PubMed

References

    1. EMBO Rep. 2014 Jun;15(6):642-56 - PubMed

References

    1. Cell Death Dis. 2018 Feb 7;9(2):168 - PubMed

References

    1. Lancet Oncol. 2015 Jun;16(6):645-55 - PubMed

References

    1. Nat Cell Biol. 2011 Aug 01;13(8):877-83 - PubMed

References

    1. J Cell Physiol. 2011 Apr;226(4):928-39 - PubMed

References

    1. Nat Rev Cancer. 2013 Apr;13(4):246-57 - PubMed

References

    1. PLoS One. 2014 Jun 19;9(6):e100664 - PubMed

References

    1. J Clin Invest. 2016 Jan;126(1):254-65 - PubMed

References

    1. Oncogene. 2017 Jun 22;36(25):3528-3540 - PubMed

References

    1. Oncotarget. 2017 Jul 31;8(37):62286-62297 - PubMed

References

    1. Mol Cancer Res. 2008 Jul;6(7):1232-49 - PubMed

References

    1. Proc Natl Acad Sci U S A. 2017 Aug 22;114(34):E7159-E7168 - PubMed

References

    1. Cell Death Dis. 2018 Jan 24;9(2):85 - PubMed

References

    1. Mol Biol Int. 2012;2012:263267 - PubMed

References

    1. Nat Rev Mol Cell Biol. 2017 Dec;18(12):758-770 - PubMed

References

    1. J Clin Oncol. 2003 Feb 15;21(4):631-7 - PubMed

References

    1. Semin Cancer Biol. 2012 Apr;22(2):79-86 - PubMed

References

    1. Pharmacol Ther. 2018 Jun;186:60-72 - PubMed

References

    1. Nat Rev Genet. 2016 May;17(5):272-83 - PubMed

References

    1. Trends Cell Biol. 2018 Apr;28(4):287-301 - PubMed

References

    1. Cancer Res. 2011 Apr 1;71(7):2728-38 - PubMed

References

    1. Clin Cancer Res. 2018 Jan 15;24(2):445-459 - PubMed

References

    1. J Invest Dermatol. 2018 Oct;138(10):2205-2215 - PubMed

References

    1. Nat Cell Biol. 2018 Aug;20(8):888-899 - PubMed

References

    1. J Clin Invest. 2017 Dec 1;127(12):4498-4515 - PubMed

References

    1. J Biol Chem. 2009 Aug 21;284(34):23094-106 - PubMed

References

    1. Oncogene. 2012 Jan 5;31(1):13-26 - PubMed

References

    1. Cell Cycle. 2017 Apr 18;16(8):795-801 - PubMed

References

    1. Oncogene. 2012 Aug 16;31(33):3818-25 - PubMed

References

    1. Biotechniques. 2006 Dec;41(6):694, 696, 698 - PubMed

References

    1. Cancer Cell. 2016 Apr 11;29(4):452-463 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback